InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,549.90
(
0.74%
)
US TECH 100
19,784.80
(
0.73%
)
Dow Jones
39,293.98
(
-0.04%
)
Brent Oil
87.58
(
0.28%
)
Bitcoin
56,490.38
(
-0.87%
)
Post# of 252490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119978
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 221660

Friday, 11/02/2018 8:11:25 AM

Friday, November 02, 2018 8:11:25 AM

Post# of 252490
In a decision that surprises me, ADXS will continue the phase-3 AIM2CERV study in adjuvant cervical cancer, possibly with an earlier interim analysis that will include a futility test. Meanwhile, ADXS-NEO reamins on track to report initial data in 1H19.

PR:
https://www.businesswire.com/news/home/20181102005079/en/Advaxis-Update-Clinical-Pipeline

CC at 11am ET.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up